ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

QLS5308

A development code. Also written as “QLS5308 IV infusion”.

Its studies are led by Qilu Pharmaceutical.

Furthest: phase 1, since Mar 5, 20261 company-led study, 1 open or runningNext primary completion: Jun 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Qilu Pharmaceutical11 open or runningphase 1since Mar 5, 2026Mar 5, 2026Jun 2027phase 1 · NCT07462442

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 5, 2026First study: phase 1 study in Metastatic Solid TumorsFirst studyNCT07462442 · 192 planned

Ahead

  1. Jun 2027Primary completion: phase 1 study in Metastatic Solid TumorsNCT07462442

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07462442Metastatic Solid Tumors1Not yet recruitingJun 2027192

How it is read

Names in the registry

  • “QLS5308 IV infusion”, 1 entry

Codes read as this program: QLS5308.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.